Cocrystal Pharma, Inc. (NASDAQ:COCP) Sees Significant Decline in Short Interest

Cocrystal Pharma, Inc. (NASDAQ:COCP) was the target of a large decrease in short interest during the month of September. As of September 30th, there was short interest totaling 175,246 shares, a decrease of 45.7% from the September 15th total of 322,748 shares. Currently, 1.5% of the shares of the company are sold short. Based on an average trading volume of 54,337 shares, the short-interest ratio is currently 3.2 days.

Cocrystal Pharma Stock Performance

Shares of COCP traded down $0.01 during midday trading on Thursday, hitting $1.03. 45,535 shares of the stock were exchanged, compared to its average volume of 812,228. The firm has a market cap of $19.84 million, a P/E ratio of -1.36 and a beta of 1.48. The stock has a fifty day simple moving average of $1.13 and a 200 day simple moving average of $1.14. Cocrystal Pharma has a 52-week low of $0.76 and a 52-week high of $2.03.

Cocrystal Pharma (NASDAQ:COCP) last issued its quarterly earnings results on Thursday, August 13th. The company reported ($0.23) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.17) by ($0.06). The firm had revenue of $0.11 million for the quarter, compared to analyst estimates of $0.10 million. As a group, equities research analysts forecast that Cocrystal Pharma will post -0.69 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of research analysts have weighed in on the stock. Weiss Ratings downgraded shares of Cocrystal Pharma from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Friday, August 21st. HC Wainwright reaffirmed a “buy” rating on shares of Cocrystal Pharma in a research note on Friday, October 9th. One analyst has rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Hold”.

Cocrystal Pharma Company Profile

Cocrystal Pharma, Inc is a clinical-stage biotechnology company focused on discovering and developing antiviral therapies. The company uses a structure-based drug discovery platform to identify small-molecule compounds designed to interfere with essential viral replication proteins.

Its research programs have targeted a range of viral diseases, including influenza A, norovirus and coronaviruses. Cocrystal’s development activities have included orally administered antiviral candidates intended for the treatment or prevention of viral infections, with programs advancing through a combination of preclinical research and clinical development.

Founded in 2007 and formerly known as BioZone Pharmaceuticals, the company adopted the Cocrystal Pharma name after combining with Cocrystal Discovery in 2015.